focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
another Govt U-turn...
A shark is teaching his kid how to eat BoJo's cronies
and he says "look son, first you swim full force to a crony but at the last second, you turn away. Then you swim at him/ her full force again, but again at the last second you swim away. Then you can go back and eat the cronies."
The son looks confused and asks, "But dad, why can't we just go eat the cronies the first time?"
Dad replies "Well, you can but why would you want to eat him/ her when they are still full of ****E ?"
I can see how the tone of sentiment has dropped in this thread, especially as it's been a difficult 6 months. The depths of patience has really been needed.....It's 2021 has already proven to be busy for NCYT, H1 figures have shown that already...H2 by default due to seasonality will be even busier and add the newer world market too, including new products added to the range...In the past practically all the business came from the the DHSC....now 60% is private sector....how can the fundamentals go backwards?....they can't IMO
NCYT will be going through a transitional period especially with DA commencing in October. Looking at his background, IMO he has a much more sales focused background. GM did a great job setting up an impressive portfilio and being a first responder to providing tests to the pandemic....I would say GM has pretty much been flat out since 2020, to supply the demand and to also come up with new innovations......Now there's other COVID test suppliers, keeping ahead of the game for diagnostics will be key for DA. I also get a sense that DA will understand the importance of the right information to keep it's shareholders and SP happy....onwards and upwards :-)
old BoJo certainly does't like the French or the Scots......the Govt must have a deal with AZN (as now allowed a profit margin on it's vaccine) and Pfizer, which will continue to bonus bonus BoJo and his cronies.
They can shake all they want, I'm still holding.
I can see testing being fully regulated (not just UKAS) which I feel is a good thing. Even home testing needs more scrutinity as so much testing abuse goes on.
It's impossible to think that variant PCR testing will not carry on, as they need to understand point of origin of any new virus coming into the UK. If the Govt doesn't want to know, well that's plain incompetent....this Govt has had more U-turns than a London black taxi :-)
what a time to think about introducing it Oct 1st, the beginning of any virus season....and how will new vaccines be created of there's no prediction modelling that's based on testing.... it's idiotic.... the NHS backlog is getting bigger by the week, cos it's under pressure.... this will tip it over the edge
yeah, sad for all concerned.
Ignore the rate that's garbage.
The hospitalisations is the one to watch, as it's bringing the NHS to it's knees....the backlog is being pushed back even further to allow for the extra case load... not good
Oxford Nanopore also said that it raised another £202 million (and is sitting on no cash) from private placements in April of this year. In March, the firm announced plans to go public in the second half of the year; however, in the filing it said that "the timing of the IPO is not under the control of the company, due to market condition."
In April, the UK Department of Health and Social Care terminated a contract for LamPore SARS-CoV-2 testing kits after determining it no longer needed them.
....I wish them the very best ;-)
It's difficult to gauge NCYT's sequencing comparison other than looking at turnover of the 2 companies as a guide for business.
Oxford Nanopore reported 2020 revenues of £113.9 million
Novacyt reported 2020 revenues of £277 million
I know that Novacyt's bioinformatics reports into COG UK.